Core Viewpoint - The company, Saifen Technology, is expected to achieve significant revenue and profit growth in the first half of 2025, driven by its focus on analytical chromatography and industrial purification sectors, alongside strong market demand and strategic partnerships [1][2]. Company Performance - The company forecasts revenue between 180 million to 186 million yuan, representing a year-on-year growth of 18% to 22% [1]. - Expected net profit attributable to shareholders is projected to be between 51 million to 55 million yuan, indicating a year-on-year increase of 34% to 44% [1]. - The net profit after deducting non-recurring gains and losses is anticipated to be between 45 million to 47 million yuan, reflecting a year-on-year growth of 18% to 23% [1]. Market Position and Strategy - Saifen Technology holds three core technologies: microspheres, surface modification, and functional group ligands, and has established strategic partnerships with leading companies in the antibody, insulin, GLP-1, and recombinant protein sectors [1]. - The company is actively developing purification solutions for oligonucleotides, collagen, and blood products, enhancing its competitive edge across various segments of the biopharmaceutical market [1]. Industry Trends - The Chinese biopharmaceutical chromatography medium market is projected to reach between 6 billion to 9 billion yuan, accounting for approximately 15% to 20% of the global market [2]. - There is a strong trend towards domestic substitution in the industry, with leading domestic companies gaining market advantages through technological depth, scale production capabilities, and quality systems [2]. - The company is expanding its core product capacity and shortening delivery times to meet the rapidly growing market demand, with a significant capacity expansion project underway at its Yangzhou factory [2].

[Current Period Performance Forecast](index=1&type=section&id=Item%201.%20Current%20Period%20Performance%20Forecast) The company forecasts H1 2025 revenue of RMB 180-186 million, with net profit attributable to shareholders of RMB 51-55 million 2025 Semi-Annual Performance Forecast | Indicator | Estimated Amount (Million RMB) | YoY Growth Rate | | :--- | :--- | :--- | | Operating Revenue | 180.00 - 186.00 | 18% - 22% | | Net Profit Attributable to Shareholders | 51.00 - 55.00 | 34% - 44% | | Net Profit Excluding Non-Recurring Items | 45.00 - 47.00 | 18% - 23% | - This performance forecast has not been audited by a certified public accountant[4](index=4&type=chunk) [Prior Period Performance](index=1&type=section&id=Item%202.%20Prior%20Period%20Performance) H1 2024 results, including RMB 152 million revenue and RMB 38.08 million net profit, serve as the comparative basis for the current forecast 2024 Semi-Annual Performance Review | Indicator | Amount | | :--- | :--- | | Operating Revenue | RMB 152.4927 million | | Net Profit Attributable to Shareholders | RMB 38.0793 million | | Net Profit Excluding Non-Recurring Items | RMB 38.0924 million | | Earnings Per Share | RMB 0.10 | [Analysis of Performance Changes](index=2&type=section&id=Item%203.%20Main%20Reasons%20for%20Performance%20Changes) Performance growth is driven by strategic focus on core areas, market expansion, and leveraging R&D to acquire new clients and boost repeat purchases - The company's strategy focuses on two core areas: analytical chromatography and industrial purification, with continuous market expansion[8](index=8&type=chunk) - Leveraging product performance and independent R&D advantages, the company continuously develops new client projects and actively promotes repeat purchases from existing clients, achieving expanded business scale and stable profitability enhancement[8](index=8&type=chunk) [Risk Warning and Other Notes](index=2&type=section&id=Item%204.%20Risk%20Warning) The company confirms no major uncertainties affecting the forecast but reminds investors that the preliminary data is unaudited - The company states that as of the announcement date, there are no significant uncertainties affecting the accuracy of this performance forecast[9](index=9&type=chunk) - The company reminds that the forecast data is preliminary and unaudited, and specific financial data will be subject to the officially disclosed 2025 semi-annual report; investors are advised to be aware of investment risks[9](index=9&type=chunk)[10](index=10&type=chunk)

赛分科技公告，预计2025年半年度实现营业收入1.8亿元到1.86亿元，与上年同期相比，将增加人民币 2750.73万元到3350.73万元，同比增长18%到22%。预计实现归属于母公司所有者的净利润5100万元到 5500万元，与上年同期相比，将增加人民币1292.07万元到1692.07万元，同比增长34%到44%。预计实 现归属于母公司所有者扣除非经常性损益后的净利润4500万元到4700万元，与上年同期相比，将增加人 民币690.76万元到890.76万元，同比增长18%到23%。 ...

Core Viewpoint - The announcement details the upcoming listing and circulation of restricted shares for Suzhou Saifen Technology Co., Ltd., which will occur on July 10, 2025, following the expiration of a six-month lock-up period for shares allocated through offline placement [1][2]. Group 1: Listing Details - The total number of shares to be listed is 2,975,050, representing 0.71% of the company's total share capital [4]. - The shares are part of the company's initial public offering (IPO) and are subject to a six-month lock-up period that began on January 10, 2025 [2][3]. - The company received approval from the China Securities Regulatory Commission for its IPO, allowing it to issue a total of 49,975,690 shares, with a total share capital of 416,464,084 shares post-IPO [1][2]. Group 2: Shareholder Commitments - Shareholders of the restricted shares have committed to a lock-up period of six months, with 10% of their allocated shares subject to this restriction [2][3]. - As of the announcement date, all shareholders have adhered to their commitments, ensuring no issues that would affect the upcoming circulation of restricted shares [2][3]. Group 3: Underwriter's Verification - The underwriter, CITIC Securities Co., Ltd., has confirmed that all shareholders have complied with their lock-up commitments, and the details regarding the circulation of restricted shares meet regulatory requirements [3].

证券代码：688758 证券简称：赛分科技 公告编号：2025-026 重要内容提示： 本次股票上市类型为首发限售股份；股票认购方式为网下，上市股数为 2,975,050股。 本次股票上市流通总数为2,975,050股。 本次股票上市流通日期为2025 年 7 月 10 日。 一、本次上市流通的限售股类型 根据中国证券监督管理委员会（以下简称"中国证监会"）于 2024 年 8 月 22 日出具的《关于同意苏州赛分科技股份有限公司首次公开发行股票注册的批复》 （证监许可〔2024〕1204 号），公司获准首次向社会公众公开发行人民币普通股（A 股）股票 4,997.5690 万股，并于 2025 年 1 月 10 日在上海证券交易所科创板上市。 公司首次公开发行股票完成后，总股本为 416,464,084 股，其中有限售条件流通 股 376,959,798 股，占公司总股本的 90.51%，无限售条件流通股 39,504,286 股， 占公司总股本的 9.49%。 本次上市流通的限售股为公司首次公开发行网下配售限售股，股份数量为 2,975,050 股，占公司总股本的比例为 0.71%。上述股份锁定期为自公司 ...

中信证券股份有限公司 关于苏州赛分科技股份有限公司 首次公开发行网下配售限售股份上市流通的核查意见 中信证券股份有限公司（以下简称"中信证券"、"保荐人"）作为苏州赛 分科技股份有限公司（以下简称"赛分科技"、"公司"）首次公开发行股票并 在科创板上市的保荐人，根据《证券发行上市保荐业务管理办法》《上海证券交 易所科创板股票上市规则》 等有关法律法规和规范性文件的要求，就赛分科技 首次公开发行网下配售限售股份上市流通的事项进行了专项核查： 一、本次上市流通的限售股类型 根据中国证券监督管理委员会（以下简称"中国证监会"）于 2024 年 8 月 22 日出具的《关于同意苏州赛分科技股份有限公司首次公开发行股票注册的批 复》（证监许可〔2024〕1204 号），公司获准首次向社会公众公开发行人民币 普通股（A 股）股票 4,997.5690 万股，并于 2025 年 1 月 10 日在上海证券交易所 科创板上市。公司首次公开发行股票完成后，总股本为 416,464,084 股，其中有 限售条件流通股 376,959,798 股，占公司总股本的 90.51%，无限售条件流通股 39,504,286 股，占公司总股 ...

Core Insights - A total of 51 new companies were listed on the Shanghai Stock Exchange, Shenzhen Stock Exchange, and Beijing Stock Exchange from January to June 2025, raising a total of 37.3 billion yuan [1] - Among these, 7 companies were listed on the Sci-Tech Innovation Board, collectively raising 5.619 billion yuan [1] Listing Details - The 7 companies that chose the first set of listing standards include: - Ying Shi Innovation (688775.SH) listed on June 11, 2025, raising 1.93807 billion yuan with underwriting fees of 158.3475 million yuan [1] - Han Bang Technology (688755.SH) listed on May 16, 2025, raising 500.94 million yuan with underwriting fees of 37.2891 million yuan [1] - Sheng Ke Nano (688757.SH) listed on March 25, 2025, raising 366.21 million yuan with underwriting fees of 43.9448 million yuan [1] - Hai Bo Si Chuang (688411.SH) listed on January 27, 2025, raising 861.1 million yuan with underwriting fees of 66.4722 million yuan [1] - Xing Fu Electronics (688545.SH) listed on January 22, 2025, raising 1.168 billion yuan with underwriting fees of 82.0755 million yuan [1] - Si Kan Technology (688583.SH) listed on January 15, 2025, raising 568.82 million yuan with underwriting fees of 46.0744 million yuan [1] - Sai Fen Technology (688758.SH) listed on January 10, 2025, raising 215.89 million yuan with underwriting fees of 25.283 million yuan [1] Listing Standards - The listing standards for the Sci-Tech Innovation Board require either: - An expected market value of no less than 1 billion yuan, positive net profits for the last two years, and a cumulative net profit of no less than 50 million yuan, or - An expected market value of no less than 1 billion yuan, positive net profit for the last year, and operating revenue of no less than 100 million yuan [1]

Group 1 - The resignation of Mr. Nie Yingqing from the board of Suzhou Saifen Technology Co., Ltd. is due to retirement, and he will no longer hold any position in the company after his resignation [1][2] - The resignation will take effect immediately upon delivery to the board and will not affect the company's daily management or operations significantly [2][3] - The company will proceed with the necessary procedures to complete the board member replacement in accordance with legal requirements [2]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 苏州赛分科技股份有限公司（以下简称"公司"）于近日收到公司保荐人中 信证券股份有限公司（以下简称"中信证券"）出具的《关于更换保荐代表人的 函》。中信证券作为公司首次公开发行股票并在科创板上市项目（以下简称"首 发上市项目"）的保荐人和持续督导机构，原指派保荐代表人刘拓先生、李雨修 先生具体负责公司持续督导工作，法定持续督导期限至 2028 年 12 月 31 日。现 因原保荐代表人李雨修先生工作变动，不再继续担任公司首发上市项目持续督导 保荐代表人。 证券代码：688758 证券简称：赛分科技 公告编号：2025-025 苏州赛分科技股份有限公司 关于变更持续督导保荐代表人的公告 为保证公司持续督导工作的有序进行，中信证券委派郑染子女士（简历详见 附件）接替李雨修先生担任公司持续督导保荐代表人，继续履行相关职责，持续 督导期至 2028 年 12 月 31 日。本次保荐代表人变更后，公司首发上市项目持续 督导期保荐代表人为刘拓先生和郑染子女士。 公司董事会对李雨修先生在公司 ...

证券代码：688758 证券简称：赛分科技 公告编号：2025-024 苏州赛分科技股份有限公司（以下简称"公司"）董事会近期收到公司董事 聂迎庆先生提交的书面辞职报告。聂迎庆先生因退休，申请辞去公司董事职务， 辞职后聂迎庆先生将不再担任公司任何职务。根据《公司法》《公司章程》等规 定，上述辞职报告自送达董事会之日起生效。 | 聂迎庆 | | | | 姓名 | | | | --- | --- | --- | --- | --- | --- | --- | | 董事 | | | 职务 | | 离任 | | | 月 30 | 2025 年 | | 间 | | 离任时 | | | 日 月 6 | 6 2027 | | 到期日 | | 原定任期 | | | 日 | 年 9 | | | | | | | 离任 | 退休 | | 原因 | | 离任 | | | 否 | | 任职 | 股子公司 | 司及其控 | 在上市公 | 是否继续 | | 不适用 | 是 | 承诺 | 适用） 的公开 | 务（如 行完毕 | 具体职 在未履 | 是否存 | 二、董事离任对公司的影响 根据《公司法》《上海证券交易所科创板股票上市规则》《公司 ...